Berman Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Berman Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$3K	Buy	+43	New	+$4.46K	﹤0.01%	1592

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's KPTI Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2021: 43 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #1592 among its holdings.

134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

Berman Capital Advisors held 43 shares of Karyopharm Therapeutics worth $3K as of Q3 2021.
Karyopharm Therapeutics was a new Berman Capital Advisors position in Q3 2021.
Karyopharm Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1592 holding.
134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.